Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 18/20 | 0.51 |
| ▸ | PDE4A | P27815 | 18/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841958 | 0.94 | PDE4B (0.53) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6660923 | 0.93 | PDE4A (0.50) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6662790 | 0.93 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CPOLB | |
| SCHEMBL6663528 | 0.90 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CPOLB | |
| SCHEMBL6656329 | 0.90 | PDE4A (0.48) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6842620 | 0.90 | PDE4A (0.49) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL7802865 | 0.90 | PDE4A (0.53) | PDE4DPDE4APDE4BPDE4CPOLB | |
| SCHEMBL7792755 | 0.90 | PDE4D (0.53) | PDE4DPDE4APDE4BPDE4CPOLB | |
| SCHEMBL7798856 | 0.90 | PDE4D (0.53) | PDE4DPDE4APDE4BPDE4CPOLB | |
| SCHEMBL144875 | 0.89 | PDE4A (0.49) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1435958-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GmbH (DE) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003032993-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GMBH (DE) | 2003-04-24 | — | — | WO | disclosed |
| US-5859008-A | Arylalkyl diazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-01-12 | — | — | US | disclosed |
| EP-0763534-A1 | Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GmbH (DE) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | PDE4A, PDE3A, PDE3B | PDE4D 12/4885PDE4A 1/4885PDE4B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.